Skip to main content
8750 search results for:

Pseudomonas Aeruginosa Pneumonia 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 15-05-2024 | Pseudomonas Aeruginosa | Online First

    Exendin-4 blockade of T1R2/T1R3 activation improves Pseudomonas aeruginosa-related pneumonia in an animal model of chemically induced diabetes

    Diabetes mellitus (DM) is a rapidly growing global endemic disease and is generally accepted as an independent risk factor for lower respiratory tract infections [ 1 , 2 ]. Accumulating investigations have revealed that compared to a healthy lung …

  2. Open Access 29-12-2023 | Imipenem | OriginalPaper

    Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa

    Carbapenem-resistant Gram-negative bacilli (CRGNB) are a major public health problem, recently described by WHO as a global crisis [ 1 ]. Since nosocomial and healthcare-associated infections caused by CRGNB organisms significantly increase …

  3. Open Access 01-12-2023 | Pseudomonas Aeruginosa | OriginalPaper

    A score to predict Pseudomonas aeruginosa infection in older patients with community-acquired pneumonia

    Community-acquired pneumonia (CAP) is lung infection that started outside the hospital or within 48 h of hospital admission [ 1 ]. It is a prevalent infectious disease affecting the elderly, with more than 30–40% of cases hospitalized [ 2 ].

  4. Open Access 01-12-2023 | Antibiotic | Letter

    Monotherapy or combination antibiotic therapy in the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia

  5. Open Access 01-12-2023 | Amikacin | OriginalPaper

    Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia

    Current guidelines for the management of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) stress the need for preventive strategies and accurate etiologic diagnosis [ 1 , 2 ]. Unfortunately, routinely employed antibiotic …

  6. Open Access 01-12-2023 | Antibiotic | OriginalPaper

    Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial

    Ventilator-associated pneumonia (VAP) is one of the most frequent ICU-acquired complications. VAP affects between 5 and 40% of mechanically ventilated patients [ 1 ] and is associated with prolonged durations of mechanical ventilation, of ICU …

  7. 26-05-2022 | Antibiotic | Letter

    Shorter might not always be better: the case for longer antibiotic therapy for Pseudomonas aeruginosa pneumonia

  8. 06-06-2022 | Antibiotic | Letter

    Shorter might not always be better: the case for longer antibiotic therapy for Pseudomonas aeruginosa pneumonia. Reply of the Editor in Chief

  9. 21-06-2022 | Antibiotic | Erratum

    Correction to: Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial

    In this article, a few mistakes have been corrected and a few sentences have been changed in the abstract, in the take-home message, and in the text. Finally, there was a mistake in Supplementary file 2; it has now been replaced with the correct …

  10. 13-05-2022 | Antibiotic | OriginalPaper

    Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial

    Ventilator-associated pneumonia (VAP) remains a major cause of morbidity and mortality in intensive care units (ICUs), accounting for 25% of infections in the ICU patients. Despite guidelines frame the treatment of VAP [ 1 – 3 ], several …

  11. Open Access 01-02-2022 | Imipenem | BriefCommunication

    Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020

    Pseudomonas aeruginosa isolates were consecutively collected from patients with pneumonia in 29 medical centers in 2020 and susceptibility tested by broth microdilution method. Ceftazidime-avibactam (95.5% susceptible), imipenem-relebactam (94.3% …

  12. Open Access 01-12-2020 | Pneumonia | OriginalPaper

    Characterization of the virulence of Pseudomonas aeruginosa strains causing ventilator-associated pneumonia

    Pseudomonas aeruginosa is one of the most common causes of ventilator-associated pneumonia (VAP), with high mortality rates (approximately 13%), prolonged hospital stays and increasing hospital costs [ 1 ]. VAP is a nosocomial lung infection that …

  13. Open Access 01-12-2020 | Pseudomonas Aeruginosa | Erratum

    Correction to: Characterization of the virulence of Pseudomonas aeruginosa strains causing ventilator-associated pneumonia

    An amendment to this paper has been published and can be accessed via the original article.

  14. Open Access 01-12-2020 | Pneumonia | OriginalPaper

    Multiple cross displacement amplification-a more applicable technique in detecting Pseudomonas aeruginosa of ventilator-associated pneumonia (VAP)

    Ventilator-associated pneumonia (VAP) develops in intensive care unit (ICU) patients that have been mechanically ventilated for at least 48 h [ 1 ]. The infection rate was related to disease severity and the degree of organ failure [ 2 ]. Further …

  15. Open Access 01-12-2019 | Community-Acquired Pneumonia | OriginalPaper

    Measuring the in-hospital costs of Pseudomonas aeruginosa pneumonia: methodology and results from a German teaching hospital

    Pneumonia presents an ongoing healthcare challenge. Community-acquired cases account for a considerable number of hospitalizations [ 1 , 2 ], and hospital-acquired pneumonia is a common complication in both ventilated [ 3 ] and non-ventilated [ 4 ] …

  16. Open Access 01-12-2019 | Antibiotic | OriginalPaper

    A case report of community-acquired Pseudomonas aeruginosa pneumonia complicated with MODS in a previously healthy patient and related literature review

    Pseudomonas aeruginosa is a gram-negative aerobic bacterium that can cause several types of infection including wound, urinary tract, and respiratory tract infections. The earliest description of P. aeruginosa pneumonia dates back to 1917 [ 1 ]. As …

  17. Open Access 01-12-2019 | Ciprofloxacin | OriginalPaper

    Quorum quenching intervened in vivo attenuation and immunological clearance enhancement by Solanum torvum root extract against Pseudomonas aeruginosa instigated pneumonia in Sprague Dawley rats

    Bacteria interact with each other using chemical signalling molecules called autoinducers by a density dependent mechanism termed as quorum sensing. This enables the synchronization of large bacterial group activities such as pigment production …

  18. Open Access 01-12-2018 | OriginalPaper

    Lower respiratory tract microbial composition was diversified in Pseudomonas aeruginosa ventilator-associated pneumonia patients

    Ventilator-associated pneumonia (VAP) is a frequent complication in patients requiring mechanical ventilation and the associated mortality ranges from 20 to 50% [ 1 , 2 ]. Pseudomonas aeruginosa is one of the most common pathogens causing VAP and …

  19. 01-08-2018 | OriginalPaper

    Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case–case–control study

    Acute bacterial pneumonia is a leading cause of morbidity and mortality in the USA [ 1 , 2 ]. Although previously considered a predominantly hospital-acquired pathogen, Pseudomonas aeruginosa has emerged as a potential cause of community-onset …

  20. 01-07-2018 | Letter

    Relative risk and population-attributable fraction of ICU death caused by susceptible and resistant Pseudomonas aeruginosa ventilator-associated pneumonia: a competing risks approach to investigate the OUTCOMEREA database

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.